COMPANY
Iambic Therapeutics
Our AI technologies, Enchant and NeuralPLexer, drive a high-throughput experimental platform that converts molecular designs into biological insights each week. From company website Source · Oct 12, 2026
Since the raise (2026-09-09, SEC Form D): 30 of 30 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| IT Support Specialist | San Diego, California, United States | Oct 19, 2026 | Oct 20, 2026 |
| Sr. Project Manager, Clinical Development | San Diego, California, United States | Oct 8, 2026 | Oct 8, 2026 |
| Sr Associate Scientist I or II, Medicinal Chemistry | San Diego, California, United States | Oct 5, 2026 | Oct 8, 2026 |
| Principal Scientist, Medicinal Chemistry | San Diego, California, United States | Oct 5, 2026 | Oct 8, 2026 |
| Principal / AD / Director, Agentic AI | San Diego, California, United States | Sep 30, 2026 | Oct 8, 2026 |
Funding and NIH signals
- SEC Form D raise Raised $65.97M in debt securities (Form D filed Sep 9, 2026); +2 other Form D filings in the last 12 months; since then posted 16 roles. SEC Form D 0001997038-26-000002 (Sep 9, 2026)
Evidence (3 events)
- Sep 9, 2026 · SEC Form D 0001997038-26-000002
Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 66500000; Total Amount Sold: 65965000; Federal exemptions: 06b - Apr 8, 2026 · SEC Form D 0001997038-26-000001
Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2026-04-08; Industry Group: Biotechnology; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 49999996; Total Amount Sold: 27769668; Federal exemptions: 06b - Nov 21, 2025 · SEC Form D 0001997038-25-000002
Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2025-11-21; Industry Group: Biotechnology; Date of First Sale: 2025-11-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 124999970; Total Amount Sold: 99269270; Federal exemptions: 06b
- Sep 9, 2026 · SEC Form D 0001997038-26-000002
Raises and deals from press releases
- Deal Takeda deal · amount not disclosed · announced Feb 9, 2026 Company release ↗
Source quote
- Feb 9, 2026 · Company release ↗
“San Diego, CA and Cambridge, MA – February 9, 2026 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration”
- Feb 9, 2026 · Company release ↗
Timeline
Upcoming milestones
- 2027-12 (ESTIMATED) · 1 · A Phase 1/1b Study of IAM1363 in HER2 Cancers · NCT06253871
Open jobs 30
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| IT Support Specialist | San Diego, California, United States | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Sr. Project Manager, Clinical Development | San Diego, California, United States | Oct 8, 2026 | Oct 8, 2026 | Senior |
| Sr Associate Scientist I or II, Medicinal Chemistry | San Diego, California, United States | Oct 5, 2026 | Oct 8, 2026 | Mid |
| Principal Scientist, Medicinal Chemistry | San Diego, California, United States | Oct 5, 2026 | Oct 8, 2026 | Senior |
| Principal / AD / Director, Agentic AI | San Diego, California, United States | Sep 30, 2026 | Oct 8, 2026 | Senior |
| Software Engineer I/II - Scientific Computing | Boston, MA, US | Sep 25, 2026 | Oct 8, 2026 | Mid |
| Sr. Associate Scientist I / II – High Throughput Chemistry | San Diego, California, United States | Sep 25, 2026 | Oct 8, 2026 | Mid |
| Research Scientist I / II – High Throughput Chemistry | San Diego, California, United States | Sep 24, 2026 | Oct 8, 2026 | Mid |
| Lead Clinical Data Manager | San Diego, California, United States | Sep 24, 2026 | Oct 8, 2026 | Senior |
| Senior Analyst, Corporate FP&A | San Diego, California, United States | Sep 23, 2026 | Oct 8, 2026 | Senior |
| Associate Director, SEC Reporting and Technical Accounting | San Diego, California, United States | Sep 21, 2026 | Oct 8, 2026 | Senior |
| Associate Director, Drug Safety | San Diego, California, United States | Sep 16, 2026 | Oct 8, 2026 | Senior |
| Associate Director, Procurement | San Diego, California, United States | Sep 14, 2026 | Oct 8, 2026 | Senior |
| Sr Manager, FP&A - Discovery R&D | San Diego, California, United States | Sep 12, 2026 | Oct 8, 2026 | Senior |
| Director, Compensation, Benefits and HR Systems | San Diego, California, United States | Sep 10, 2026 | Oct 8, 2026 | Senior |
| Associate Medical Director/Medical Director | San Diego, California, United States | Sep 10, 2026 | Oct 8, 2026 | Senior |
| Research Scientist I/II, Purification Sciences | San Diego, California, United States | Sep 9, 2026 | Oct 8, 2026 | Mid |
| Senior Associate Scientist I/II, Purification Sciences | San Diego, California, United States | Sep 9, 2026 | Oct 8, 2026 | Mid |
| Director/Senior Director, Immunology | San Diego, California, United States | Sep 8, 2026 | Oct 8, 2026 | Senior |
| Principal Medical Writer | San Diego, California, United States | Sep 4, 2026 | Oct 8, 2026 | Senior |
| Research Scientist I/II, Bioanalytical Sciences & Assay Development | San Diego, California, United States | Aug 31, 2026 | Oct 8, 2026 | Mid |
| Machine Learning Scientist – Clinical Prediction | Boston, MA, US | Aug 31, 2026 | Oct 8, 2026 | Mid |
| Machine Learning Scientist — Large Multimodal Models (Post-Training) | Bristol, England, United Kingdom | Aug 27, 2026 | Oct 8, 2026 | Mid |
| Machine Learning Scientist — Large Multimodal Models (Post-Training) | Boston, MA, US | Aug 27, 2026 | Oct 8, 2026 | Mid |
| Senior Clinical Trial Manager, Clinical Operations | San Diego, California, United States | Aug 18, 2026 | Oct 8, 2026 | Senior |
| Research Scientist I/II, Immunology | San Diego, California, United States | Aug 17, 2026 | Oct 8, 2026 | Mid |
| Research Scientist II/Senior, Computational Chemistry | San Diego, California, United States | Aug 15, 2026 | Oct 8, 2026 | Mid |
| Associate Director / Director, Regulatory Affairs - CMC | San Diego, California, United States | Aug 14, 2026 | Oct 8, 2026 | Senior |
| Senior / Executive Medical Director, Clinical Development (Oncology) | San Diego, California, United States | Aug 7, 2026 | Oct 8, 2026 | Executive |
| Research Scientist II/Senior, Discovery Machine Learning | San Diego, California, United States | Jun 15, 2026 | Oct 8, 2026 | Mid |
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | 1 | Recruiting | Mar 25, 2024 | 2027-12 (estimated) |
Raises and investors new
- Raise Private raise (SEC Form D): $66.0M sold of $66.5M offered; issuer “Iambic Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
- Raise Private raise (SEC Form D): $27.8M sold of $50.0M offered; issuer “Iambic Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
- Raise Private raise (SEC Form D): $99.3M sold of $125.0M offered; issuer “Iambic Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
- InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Iambic Therapeutics on LinkedIn (search by name, results not checked)